WO2012027261 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES

Settings

Stemming

Single Family Member

Include NPL

Feedback

Goto Application

Publication Number WO/2012/027261

Publication Date 01.03.2012

International Application No. PCT/US2011/048596

International Filing Date 22.08.2011

IPC

View more classifications

View less classifications

CPC

View more classifications

View less classifications

Applicants

AMGEN INC. [US]/[US] (AllExceptUS)
ASHTON, Kate [GB]/[US] (UsOnly)
BARTBERGER, Michael David [US]/[US] (UsOnly)
BO, Yunxin [CN]/[US] (UsOnly)
BRYAN, Marian C. [US]/[US] (UsOnly)
CROGHAN, Michael [US]/[US] (UsOnly)
FOTSCH, Christopher Harold [US]/[US] (UsOnly)
HALE, Clarence Henderson [US]/[US] (UsOnly)
KUNZ, Roxanne Kay [US]/[US] (UsOnly)
LIU, Longbin [US]/[US] (UsOnly)
NISHIMURA, Nobuko [JP]/[US] (UsOnly)
NORMAN, Mark H. [US]/[US] (UsOnly)
PENNINGTON, Lewis Dale [US]/[US] (UsOnly)
POON, Steve Fong [US]/[US] (UsOnly)
STEC, Markian Myroslaw [US]/[US] (UsOnly)
ST. JEAN, David, Joseph, Jr. [US]/[US] (UsOnly)
TAMAYO, Nuria A. [US]/[US] (UsOnly)
TEGLEY, Christopher Michael [US]/[US] (UsOnly)
YANG, Kevin Chao [US]/[US] (UsOnly)

Inventors

ASHTON, Kate
BARTBERGER, Michael David
BO, Yunxin
BRYAN, Marian C.
CROGHAN, Michael
FOTSCH, Christopher Harold
HALE, Clarence Henderson
KUNZ, Roxanne Kay
LIU, Longbin
NISHIMURA, Nobuko
NORMAN, Mark H.
PENNINGTON, Lewis Dale
POON, Steve Fong
STEC, Markian Myroslaw
ST. JEAN, David, Joseph, Jr.
TAMAYO, Nuria A.
TEGLEY, Christopher Michael
YANG, Kevin Chao

Agents

CRISSEY, Todd M.

Priority Data

61/376,141		23.08.2010		US
61/492,634		02.06.2011		US

Publication Language English (en)

Filing Language English (EN)

Designated States

View all

Title

(EN) SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES

(FR) DÉRIVÉS DE SULFONYLPIPÉRAZINE QUI INTERAGISSENT AVEC LA PROTÉINE RÉGULATRICE DE LA GLUCOKINASE POUR LE TRAITEMENT DU DIABÈTE

Abstract

(EN) The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

(FR) La présente invention concerne des composés de la formule I, ou leurs sels de qualité pharmaceutique, qui interagissent avec la protéine régulatrice de la glucokinase. De plus, la présente invention concerne des méthodes de traitement du diabète de type 2, et autres maladies et/ou états où la protéine régulatrice de la glucokinase est impliquée, à l'aide des composés, ou de leurs sels de qualité pharmaceutique. L'invention concerne également des compositions pharmaceutiques qui contiennent les composés ou leurs sels de qualité pharmaceutique.

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
D	HETEROCYCLIC COMPOUNDS
213	Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
02	having three double bonds between ring members or between ring members and non-ring members
04	having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
24	with substituted hydrocarbon radicals attached to ring carbon atoms
28	Radicals substituted by singly-bound oxygen or sulfur atoms
30	Oxygen atoms

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
D	HETEROCYCLIC COMPOUNDS
213	Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
02	having three double bonds between ring members or between ring members and non-ring members
04	having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
60	with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
62	Oxygen or sulfur atoms
70	Sulfur atoms
71	to which a second hetero atom is attached

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
D	HETEROCYCLIC COMPOUNDS
213	Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
02	having three double bonds between ring members or between ring members and non-ring members
04	having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
60	with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
72	Nitrogen atoms
74	Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
D	HETEROCYCLIC COMPOUNDS
231	Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
02	not condensed with other rings
10	having two or three double bonds between ring members or between ring members and non-ring members
14	with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
18	One oxygen or sulfur atom

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
D	HETEROCYCLIC COMPOUNDS
239	Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
02	not condensed with other rings
24	having three or more double bonds between ring members or between ring members and non-ring members
28	with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
32	One oxygen, sulfur or nitrogen atom
42	One nitrogen atom

Processing

National Phase Entries

Authority File

Settings

Feedback

Goto Application

1. WO2012027261 - SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
P	SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13	Drugs for disorders of the urinary system
12	of the kidneys

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
C	ACYCLIC OR CARBOCYCLIC COMPOUNDS
317	Sulfones; Sulfoxides
16	having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
22	with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton